MTOR and metabolic dysfunction-associated steatotic liver disease: In MASLD and HCC, DNL is controlled by mammalian target of rapamycin (mTOR), ChREBP, and SREBP1‐c that, through acetyl‐CoA carboxylase (ACC), stearoyl‐CoA desaturase 1 (SCD1), and ATP citrate lyase (ACLY), sustain lipid synthesis.40, 41